Valentín Ortiz-Maldonado

Valentín Ortiz-Maldonado is a haematologist at Hospital Clínic de Barcelona and FRCB-IDIBAPS, according to the affiliation on his 2026 HemaSphere paper. He is first author of the 2021 Molecular Therapy report of CART19-BE-01, in which 47 of 58 included patients were treated with ARI-0001 and fractionated dosing cut grade 3 or higher cytokine release syndrome in acute lymphoblastic leukaemia from 26.7% to 4.3%, and senior author of the 2026 report on varnimcabtagene autoleucel in relapsed or refractory mantle cell lymphoma, where overall response among 27 infused patients was 89%. He also first-authored the ARI-0001 reports in leukaemia with isolated extramedullary disease and in chronic lymphocytic leukaemia.